



*Just What Women
Want in Healthcare*

FOR IMMEDIATE RELEASE:

**AGILE THERAPEUTICS TO PRESENT AT
UPCOMING LIFE SCIENCE CONFERENCES**

Princeton, NJ – October 29, 2007 – Agile Therapeutics, Inc., a specialty pharmaceutical company focused on the development of innovative women’s healthcare products, today announced that Thomas Rossi, Ph.D., President and Chief Executive Officer, will present at *Acumen BioFin Rodman and Renshaw’s 9th Annual Healthcare Conference* and the *BIO Europe 2007 International Partnering Conference*. Dr. Rossi will be available for one-on-one meetings at both conferences.

The *Acumen BioFin Rodman and Renshaw’s 9th Annual Healthcare Conference* will take place from November 5 - 7, 2007 at the Palace Hotel in New York, NY. Dr. Rossi’s presentation will be held on Wednesday, November 7, 2007 at 10:50 AM in the Hubbard room located on the 5th floor. For more information please visit www.rodmanandrenshaw.com

The *BIO Europe 2007 International Partnering Conference* will take place in Hamburg, Germany at the CCH-Congress Center from November 12 - 14, 2007. Dr. Rossi’s presentation will be held on Tuesday, November 13, 2007, at 9:45 AM in room B1, level 1. For more information please visit www.ebdgroup.com/bioeurope

About Agile Therapeutics, Inc.

Agile Therapeutics is a specialty pharmaceutical company focused on the development of innovative women’s healthcare products. The company’s late-stage products are driven by a market void for a low-estrogen dose, convenient and reliable contraceptive patch. Agile is capitalizing on its executive team’s proven expertise in transdermal technology, drug development, as well as brand and fertility management to build a pipeline of women’s health products through line extensions and/or in-licensing. Agile has raised a total of \$30 million in venture funding to date. The company’s current venture investors include ProQuest, the Hillman Company, TL Ventures and PA Early Stage Partners. For more information please visit www.agiletherapeutics.com

#

Contact:
Martin Reynolds
LaVoie Group
978-745-4200 x 107
mreynolds@lavoiegroup.com